Corticotropin-releasing factor antagonists in affective disorders.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  1999-11-17

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1517/13543784.8.11.1849PMID 11139829
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Autoradiographic and in situ hybridization localization of corticotropin‐releasing factor 1 and 2 receptors in nonhuman primate brain

  1999cited by this paper
• Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications.

  1999cited by this paper
• Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress.

  1999cited by this paper
• Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.

  1999cited by this paper
• Corticotropin-releasing hormone receptor antagonists: framework design and synthesis guided by ligand conformational studies.

  1999cited by this paper
• Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines.

  1999cited by this paper
• Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines.

  1999cited by this paper
• The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress.

  1999cited by this paper
• In vitro pharmacological profile of nonpeptide CRF1 receptor antagonists, CRA1000 and CRA1001.

  1999cited by this paper
• Design, synthesis and characterization of fluorinated- and iodinated- pyrrolo[2,3-d]pyrimidines as candidates for CRF1 receptor PET/SPECT ligands

  1999cited by this paper
• Chapter 2. Recent Progress in Corticotropin-Releasing Factor Receptor Agents

  1999cited by this paper
• The role of corticotropin-releasing factor in depression and anxiety disorders.

  1999cited by this paper
• Characterization of [125I]sauvagine binding to CRH2 receptors: membrane homogenate and autoradiographic studies.

  1998cited by this paper
• Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis.

  1998cited by this paper
• Corticotrophin-releasing factor receptor antagonists

  1998cited by this paper
• Non-peptidic corticotropin-releasing hormone receptor type 1 antagonist reverses restraint stress-induced shortening of sodium pentobarbital-induced sleeping time of rats: evidence that an increase in arousal induced by stress is mediated through CRH receptor type 1.

  1998cited by this paper
• CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats

  1998cited by this paper
• The neurobiology of depression.

  1998cited by this paper
• Localization of ligand-binding domains of human corticotropin-releasing factor receptor: a chimeric receptor approach.

  1997cited by this paper
• Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist.

  1997cited by this paper
• Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist.

  1997cited by this paper
• The CRF1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist.

  1997cited by this paper
• Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors.

  1997cited by this paper
• Chapter 5. Corticotropin-Releasing Hormone (CRH) Receptors and the Discovery of Selective Non-Peptide CRH1 Antagonists

  1997cited by this paper
• ■ REVIEW : Corticotropin-releasing Factor, Stress, and Depression

  1997cited by this paper
• Design and Synthesis of a Series of Non-Peptide High-Affinity Human Corticotropin-Releasing Factor1 Receptor Antagonists

  1997cited by this paper
• Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists.

  1996cited by this paper
• Rapid microscale synthesis, a new method for lead optimization using robotics and solution phase chemistry: application to the synthesis and optimization of corticotropin-releasing factor1 receptor antagonists.

  1996cited by this paper
• CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors.

  1996cited by this paper
• A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity.

  1996cited by this paper
• In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation.

  1996cited by this paper
• Corticotrophin-releasing factor receptors: from molecular biology to drug design.

  1996cited by this paper
• Expression of corticotropin-releasing factor and its receptors in the brain of lean and obese Zucker rats.

  1996cited by this paper
• CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues.

  1995cited by this paper
• Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor

  1995cited by this paper
• Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression

  1995cited by this paper
• Physiology and pharmacology of corticotropin-releasing factor.

  1991cited by this paper
• Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study.

  1983cited by this paper
• Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin.

  1982cited by this paper
• Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin

  1981cited by this paper
• Printed in U.S.A. Copyright © 1999 by The Endocrine Society The Impact of the Nonpeptide Corticotropin-Releasing Hormone Antagonist Antalarmin on Behavioral and Endocrine Responses to Stress*

  year unknowncited by this paper
• Printed in U.S.A. Copyright © 1998 by The Endocrine Society Chronic Effects of a Nonpeptide Corticotropin-Releasing Hormone Type I Receptor Antagonist on Pituitary- Adrenal Function, Body Weight, and Metabolic Regulation*

  year unknowncited by this paper

• 3-Aminopyrazolo[4,3-c]pyridine-4,6-dione as a precursor for novel pyrazolo[4,5,1-ij][1,6]naphthyridines and pyrido[4’,3’:3,4]pyrazolo[1,5-a]pyrimidines

  2018cites this paper
• Effects of acute restraint and unpredictable chronic mild stress on brain corticotrophin releasing factor mRNA in the elevated T‐maze

  2018cites this paper
• Non-peptide ligands in the characterization of peptide receptors at the interface between neuroendocrine and mental diseases

  2013cites this paper
• Neurobiological Basis for Development of New Antidepressant Agents

  2011cites this paper
• Future Drugs for the Treatment of Depression: The Need to Look Beyond Monoamine Systems

  2009cites this paper
• Postmortem Brain Tissue of Depressed Suicides Reveals Increased Gsα Localization in Lipid Raft Domains Where It Is Less Likely to Activate Adenylyl Cyclase

  2008cites this paper
• PostmortemBrainTissueofDepressedSuicidesReveals IncreasedGsLocalizationinLipidRaftDomainsWhereIt IsLessLikelytoActivateAdenylylCyclase

  2008cites this paper
• Lipid rafts, G proteins and the etiology of and treatment for depression: progress toward a depression biomarker

  2008cites this paper
• Heteroatom-linked indanylpyrazines are corticotropin releasing factor type-1 receptor antagonists.

  2007cites this paper
• Effects of the CRF1 antagonist antalarmin on cocaine self-administration and discrimination in rhesus monkeys.

  2006cites this paper
• CRF receptor type 1 mediates continual hypoxia-induced CRF peptide and CRF mRNA expression increase in hypothalamic PVN of rats.

  2005cites this paper
• Hypothalamic hormones a.k.a. hypothalamic releasing factors.

  2005cites this paper
• The therapeutic potential of CRF1 antagonists for anxiety

  2004cites this paper
• Neuroendocrine Basis of Human Disease

  2004cites this paper
• Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

  2004cites this paper
• Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression.

  2003cites this paper
• Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future

  2003cites this paper
• Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects.

  2003cites this paper
• G protein signaling and the molecular basis of antidepressant action.

  2003cites this paper
• The Corticotropin-Releasing Factor1 Receptor Antagonist R121919 Attenuates the Behavioral and Endocrine Responses to Stress

  2003cites this paper
• Corticotropin-releasing factor antagonist attenuates stress-induced inhibition of seasonal ovarian recrudescence in the lizard Mabuya carinata.

  2002cites this paper
• Preclinical models: status of basic research in depression.

  2002cites this paper
• Differing concentrations of corticotropin-releasing factor and oxytocin in the cerebrospinal fluid of bonnet and pigtail macaques.

  2002cites this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder

  2002cites this paper
• Monoamine and neuropeptide-related function: prospects for novel therapeutics of depression

  2002cites this paper
• Crossroads of corticotropin releasing hormone, corticosteroids and monoamines. About a biological interface between stress and depression.

  2002cites this paper
• Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat.

  2002cites this paper
• Stress Hormone-Related Psychopathology: Pathophysiological and Treatment Implications

  2001cites this paper
• Antiglucocorticoid drugs in the treatment of depression

  2001cites this paper
• The cellular neurobiology of depression

  2001cites this paper
• Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat.

  2000cites this paper
• Stress and depression: from vulnerability to treatment

  2000cites this paper